Legend Biotech Corp (NAS:LEGN)

$ 50.7 0.79 (1.58%) Market Cap: 9.29 Bil Enterprise Value: 8.19 Bil PE Ratio: 0 PB Ratio: 8.01 GF Score: 69/100

Q2 2024 Legend Biotech Corp Earnings Call Transcript
Aug 09, 2024

$55.9 (-1.77%)

Earnings
Q1 2024 Legend Biotech Corp Earnings Call Transcript
May 13, 2024

$42.97 (-0.62%)

Earnings
Q4 2023 Legend Biotech Corp Earnings Call Transcript
Mar 11, 2024

$65.19 (+3.07%)

Earnings
Legend Biotech Corp at JPMorgan Healthcare Conference Transcript
Jan 09, 2024
Q3 2023 Legend Biotech Corp Earnings Call Transcript
Nov 20, 2023

$60.5 (-6.29%)

Earnings
Q2 2023 Legend Biotech Corp Earnings Call Transcript
Aug 15, 2023

$66.95 (-4.83%)

Earnings
Legend Biotech Corp at ASCO 2023 Transcript
Jun 05, 2023
Legend Biotech Corp R&D Day Transcript
Oct 03, 2022
Legend Biotech Corp at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 11, 2022
Legend Biotech Corp Hybrid KOL Event Detailing Cartitude Data Update Call Transcript
Dec 14, 2021
Legend Biotech Corp R&D Day Transcript
Oct 18, 2021
Legend Biotech Corp at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 10, 2021
Q4 2020 Legend Biotech Corp Earnings Call Transcript
Mar 18, 2021

$26.27 (-7.21%)

Earnings
Legend Biotech Corp at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 13, 2021
Legend Biotech Corp Virtual Investor KOL Event Reviewing Latest CARTITUDE-1 Data from ASH Annual Meeting Transcript
Dec 08, 2020
Legend Biotech Corp to Discuss the Management Transition Business Update Call Transcript
Aug 02, 2020

Q2 2023 Legend Biotech Corp Earnings Call Transcript

Aug 15, 2023 / 12:00PM GMT

Release Date Price: $66.95 (-4.83%)

Transcript

Operator

Good morning, and thank you for standing by. Welcome to the Legend Biotech Reports Second Quarter 2023 Financial Results. (Operator Instructions) Please be advised that today's conference is being recorded.

I would now like to turn the conference over to Jessie Yeung, Head of Investor Relations and Public Relations. Please go ahead.

Jessie Yeung

Good morning. This is Jessie Yeung, Head of Investor Relations and Public Relations at Legend Biotech. Thank you for joining our conference call today to review our second quarter 2023 performance.

Joining me on today's call are Ying Huang, our CEO; and Lori Macomber, Legend's CFO. Following the prepared remarks, we will open up the call for Q&A. We have Guowei Fang, Chief Scientific Officer; and Steve Gavel, Head of Commercial Development for the U.S. and Europe, joining the Q&A session.

During today's call, we will be making forward-looking statements, which are subject to risks and uncertainties that may cause our actual results to differ materially from those expressed or implied here

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.